$1.2 M ORDERS FOR OPSENS’ FFR PRODUCTS

OPSENS RECEIVES ORDERS WORTH $1.2 MILLION FOR ITS FFR PRODUCTS FROM JAPAN

Quebec City, Quebec, November 30, 2015 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce receipt of orders worth over $1.2 million for its products to measure Fractional Flow Reserve (“FFR”) from the Japanese market. Opsens’ FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease. The orders placed by Opsens’ Japanese distributor, a player in interventional cardiology at the head of a well-organized distribution network, more than double Opsens’ FFR revenues from fiscal year 2015.

“The receipt of these orders, during the limited market release phase for the single territory of Japan, is a very good sign,” said Louis Laflamme, President and Chief Executive Officer of Opsens. “In parallel to the progress in Japan, Opsens is also working to expand its commercial activities in several other geographical territories, which will generate strong growth for Opsens’ FFR revenue in fiscal 2016,” Laflamme concluded.

About Opsens Inc. (www.opsens.com or www.opsensmedical.com)

Opsens focuses mainly on the measure of Fractional Flow Reserve (“FFR”) in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.